Vir Biotechnology (VIR) Projected to Post Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Vir Biotechnology to post earnings of ($0.85) per share and revenue of $8.14 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $9.47 on Tuesday. The company has a market cap of $1.30 billion, a PE ratio of -2.42 and a beta of 0.64. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45. The stock has a 50-day simple moving average of $9.35 and a 200 day simple moving average of $8.49.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays decreased their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Leerink Partners raised their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Finally, JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.83.

Insider Buying and Selling at Vir Biotechnology

In other news, Director George A. Scangos sold 10,964 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the sale, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now directly owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,562 shares of company stock worth $259,693 over the last ninety days. 15.60% of the stock is currently owned by corporate insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).